• 1
    Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010; 42(suppl 3): S206-S214.
  • 2
    Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001; 2: 533-543.
  • 3
    Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol. 2005; 100: 1995-2004.
    Direct Link:
  • 4
    Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
  • 5
    Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390.
  • 6
    Benson AB 3rd, Bekaii-Saab T, Ben-Josef E, et al. Hepatobiliary cancers. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2006; 4: 728-750.
  • 7
    Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005; 42: 1208-1236.
  • 8
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003; 37: 429-442.
  • 9
    Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010; 52: 762-773.
  • 10
    Gadaleta CD, Ranieri G. Trans-arterial chemoembolization as a therapy for liver tumours: new clinical developments and suggestions for combination with angiogenesis inhibitors. Crit Rev Oncol Hematol. 2011; 80: 40-53.
  • 11
    Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer. 2009; 115: 4895-4906.
  • 12
    Kaseb AO, Hassan MM, Lin E, et al. V-CLIP: integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials [published online ahead of print December 14, 2010]. Cancer. 2010.
  • 13
    Tseng CS, Lo HW, Chen PH, Chuang WL, Juan CC, Ker CG. Clinical significance of plasma D-dimer levels and serum VEGF levels in patients with hepatocellular carcinoma. Hepatogastroenterology. 2004; 51: 1454-1458.
  • 14
    Yao DF, Wu XH, Zhu Y, et al. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2005; 4: 220-226.
  • 15
    Poon RT, Lau C, Yu WC, Fan ST, Wong J. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep. 2004; 11: 1077-1084.
  • 16
    Sergio A, Cristofori C, Cardin R, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008; 103: 914-921.
    Direct Link:
  • 17
    Xiao EH, Guo D, Bian DJ. Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells. World J Gastroenterol. 2009; 15: 4582-4586.
  • 18
    Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004; 10: 145-147.
  • 19
    Xiong YQ, Sun HC, Zhu XD, et al. Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to Adriamycin related to inhibition of survivin expression. J Cancer Res Clin Oncol. 2011; 137: 505-512.
  • 20
    Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011; 29: 3960-3967.
  • 21
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53: 1020-1022.
  • 22
    Buijs M, Vossen JA, Frangakis C, et al. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization—single-center experience. Radiology. 2008; 249: 346-354.
  • 23
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
  • 24
    Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001; 35: 421-430.
  • 25
    Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008; 100: 698-711.
  • 26
    Britten CD, Finn RS, Gomes AS, et al. A pilot study of IV bevacizumab in hepatocellular cancer patients undergoing chemoembolization (2005 ASCO Annual Meeting Proceedings) [abstract]. J Clin Oncol. 2005; 23(16S; pt I of II, June 1 suppl). Abstract 4138.
  • 27
    Ulbrich G, Pinter M, Reiberger T, et al. AVATACE-1 trial: bevacizumab as inhibitor of collateral tumor-vessel-growth during transarterial chemoembolization (TACE) for hepatocellular carcinoma—a double-blind, randomized, placebo-controlled pilot-trial. Paper presented at: 61st Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2010); October 29 to November 2, 2010; Boston, MA.
  • 28
    Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008; 26: 2992-2998.
  • 29
    Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006; 24: 1898-1903.
  • 30
    Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009; 250: 466-473.
  • 31
    Tuma RS. Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints. J Natl Cancer Inst. 2006; 98: 1272-1274.
  • 32
    Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 2009; 27: 843-850.